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Dynamics of Plasmodium
falciparum Selection After
Artemether-Lumefantrine
Treatment in Africa
To the Editor—In an article recently
published in the Journal of Infectious
Diseases, Baliraine and Rosenthal [1]
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report the selection of pfmdr1 86N, 184F,
and 1246D alleles in a parasite population
under long-term artemether-lumefantrine
treatment. They suggest that ‘‘decreased
drug sensitivity can appear long after
predicted exposure to antimalarial drugs.’’
This study supports earlier reports des-
cribing antimalarial drug–mediated
selection of pfmdr1 alleles in parasites
reinfecting successfully treated malaria
patients [2, 3].
The pharmacokinetics of artemether-
lumefantrine are such that, on average,
lumefantrine is completely cleared from
the body at around day 35 posttreatment
[4], which correlates with the reported
selective window for pfmdr1. Thus, an
explanation for the observed selection of
resistance-associated alleles outside this
window is required.
It is possible that the dynamics of an-
timalarial resistance selection can explain
the increase of associated alleles outside
the selective window. To demonstrate this,
a model (Figure 1), which was derived
from previous reports [2–4], illustrates
the increase in prevalence of this allele
beyond the 35-day selective window.
This model considers an initial pop-
ulation with an equal prevalence of 86N
and 86Y alleles (green triangles and red
circles, respectively, in Figure 1), an equal
probability of 86N and 86Y alleles ap-
pearing through mutation, and an equal
probability that either allele may be car-
ried by parasites that cause reinfections.
Two parasite populations at different
time points during the selection process
are represented at points 1 and 2 (blue
circles).
According to this model, the 86N
allele frequency increases to 0.7 during
Figure 1. Dynamics of pfmdr1 86N allele selection following artemether-lumefantrine treatment. This scheme represents the selection of parasites
carrying the 86N (lumefantrine-resistant) and 86Y (lumefantrine-sensitive) alleles (green triangles and red circles, respectively ) over time. The model
considers an initial population with an equal prevalence of 86N and 86Y alleles, an equal probability of 86N and 86Y alleles appearing through
mutation, and an equal probability that either allele may be carried by parasites that cause reinfections. The selection process for the 86N allele is
shown in a time-dependent manner; an initial selection phase is shown by population 1 (blue circle 1 ), which represents an intermediate stage in
relation to the final selected population, shown in population 2 (blue circle 2 ).
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the latter part of the clinical trial (rep-
resented by population 2 in Figure 1).
The 86N allele frequency in reinfections
is 0.75 in patients treated ,35 days
prior to reinfection and 0.6 in those
treated .35 days prior to reinfection.
To explain the apparent increase of the
resistant allele outside the 35-day selective
window, an intermediate state in the se-
lection process is shown by population 1
(Figure 1). At the early stage of the hy-
pothetical clinical trial, frequency of the
86N allele is measured at 0.75 within the
35-day lumefantrine selection window,
whereas no selection is observed (com-
pared with the initial population) outside
this window (ie, allele frequency is 0.5).
With the increase of 86N in the general
population, further reinfections occur-
ring at.35 posttreatment in ‘‘population
2’’ will carry allele frequencies reflecting
the parasite population following selec-
tion of ‘‘population 1.’’
Baliraine and Rosenthal’s [1] results
raise important questions regarding how
clinical trials of antimalarial efficacy
should be analyzed in terms of drug re-
sistance selection at the parasite pop-
ulation level. It is becoming increasingly
clear that posttreatment reinfections act
as a strong mechanism driving selection
of antimalarial resistance in Plasmodium
falciparum. This fact suggests that the
design of clinical trials of antimalarial
drug efficacy and their molecular analysis
should be carefully considered. Proce-
dures concerning follow-up periods and
duration/season of clinical trials need to
be taken into consideration, as fluctua-
tions in transmission intensity will have
a direct effect on the rate of reinfection.
The selection of drug resistance within
a parasite population is a dynamic process
that results in the accumulation of adap-
tive characteristics in a temporal manner.
Commonly, large antimalarial efficacy
trials are performed over a period of
several months. During the latter periods
of such trials, the allele frequencies of
genes linked to drug resistance within
the parasite populations may already be
altered due to the drug pressure that
results from the trial. In practical terms,
this becomes important when the allele
frequencies of the parasite population
sampled from patients at the beginning
of the trial are used as the ‘‘baseline’’ for
all comparisons, regardless of the time
point of the secondary sampling. In
summary, there is a cumulative effect of
selection of alleles associated with drug
resistance, which, in the case of analyses
of reinfections following antimalarial
treatment, may lead to an overestimation
of the selection pressure. The same
principle is applicable to the (non–drug
resistance-related) genetic background of
parasites that cause reinfections at differ-
ent points during the clinical trial.
We believe that there is a need to es-
tablish standard operational procedures
for the performance of future clinical
efficacy trials of artemisinin combination
therapy if they are to assess selection of
resistant alleles. This is particularly rele-
vant for trials conducted in Africa, where
malaria transmission intensity plays an
important etiologic role.
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